• ホーム
  • 検索結果
  • Conditional disruption of the prolyl hydroxylase domain-containing protein 2 (Phd2) gene defines its key role in skeletal development.

Conditional disruption of the prolyl hydroxylase domain-containing protein 2 (Phd2) gene defines its key role in skeletal development.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2014-04-23)
Shaohong Cheng, Weirong Xing, Sheila Pourteymoor, Subburaman Mohan
要旨

We have previously shown that the increase in osterix (Osx) expression during osteoblast maturation is dependent on the activity of the prolyl hydroxylase domain-containing protein 2 (Phd2), a key regulator of protein levels of the hypoxia-inducible factor family proteins in many tissues. In this study, we generated conditional Phd2 knockout mice (cKO) in osteoblast lineage cells by crossing floxed Phd2 mice with a Col1α2-iCre line to investigate the function of Phd2 in vivo. The cKO mice developed short stature and premature death at 12 to 14 weeks of age. Bone mineral content, bone area, and bone mineral density were decreased in femurs and tibias, but not vertebrae of the cKO mice compared to WT mice. The total volume (TV), bone volume (BV), and bone volume fraction (BV/TV) in the femoral trabecular bones of cKO mice were significantly decreased. Cross-sectional area of the femoral mid-diaphysis was also reduced in the cKO mice. The reduced bone size and trabecular bone volume in the cKO mice were a result of impaired bone formation but not bone resorption as revealed by dynamic histomorphometric analyses. Bone marrow stromal cells derived from cKO mice formed fewer and smaller nodules when cultured with mineralization medium. Quantitative RT-PCR and immunohistochemistry detected reduced expression of Osx, osteocalcin, and bone sialoprotein in cKO bone cells. These data indicate that Phd2 plays an important role in regulating bone formation in part by modulating expression of Osx and bone formation marker genes.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
Human EPO / Erythropoietin ELISA Kit, for serum, plasma, cell culture supernatants and urine
Sigma-Aldrich
Monoclonal Anti-SP7 antibody produced in mouse, clone 1C11, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-SP7, (N-terminal) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-EGLN1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-EGLN1 antibody produced in rabbit, IgG fraction of antiserum
Sigma-Aldrich
Anti-SP7 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-SP7 antibody produced in mouse, clone 2G6, purified immunoglobulin, buffered aqueous solution

ソーシャルメディア

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

研究、開発、製造

私たちは、バイオテクノロジーと医薬品の研究&開発および製造のソリューションとサービスを提供する、グローバルなライフサイエンス業界のリーディングサプライヤーです。

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates.All Rights Reserved.

当ウェブサイトのいかなる内容についても、許可なく複写することを禁じます。